UK markets close in 1 hour 3 minutes
  • FTSE 100

    6,690.10
    -25.32 (-0.38%)
     
  • FTSE 250

    20,640.13
    -153.59 (-0.74%)
     
  • AIM

    1,193.84
    -4.25 (-0.35%)
     
  • GBP/EUR

    1.1225
    -0.0056 (-0.50%)
     
  • GBP/USD

    1.3668
    -0.0062 (-0.45%)
     
  • BTC-GBP

    23,800.79
    +1,596.25 (+7.19%)
     
  • CMC Crypto 200

    646.97
    +36.98 (+6.06%)
     
  • S&P 500

    3,836.01
    -17.06 (-0.44%)
     
  • DOW

    30,956.80
    -219.21 (-0.70%)
     
  • CRUDE OIL

    52.59
    -0.54 (-1.02%)
     
  • GOLD FUTURES

    1,854.20
    -11.70 (-0.63%)
     
  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     
  • HANG SENG

    29,447.85
    -479.91 (-1.60%)
     
  • DAX

    13,877.84
    -28.83 (-0.21%)
     
  • CAC 40

    5,554.91
    -35.88 (-0.64%)
     

Arcturus Therapeutics to Present at Upcoming Investor Conference

·2-min read

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at Piper Sandler’s 32nd Annual Virtual Healthcare Conference:

The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to be Answered into 2021

Panel Presentation
Date: Tuesday, Dec 1, 2020
Time: 10:00 a.m. ET

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (200 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005982/en/

Contacts

IR and Media Contacts
Arcturus Therapeutics
Neda Safarzadeh
(858) 900-2682
IR@ArcturusRx.com

Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
ctanzi@kendallir.com